Fig. 3. Role of SARS-CoV-2 variants of concern on CoVac-1 peptides and immunogenicity.
a, Colour-coded mutations described for variants of concern are shown together with corresponding affected CoVac-1 peptides. b, c, Intensities of T cell responses (calculated spot counts) to CoVac-1 peptides as well as to the corresponding peptide pools comprising the CoVac-1-affecting mutations of B.1.1.7 and B.1.351 were assessed ex vivo by IFNγ ELISPOT assays using peripheral blood mononuclear cells from study participants of part I (n = 12) and part II (n = 24) collected on day 28 after vaccination (pCoVs) (b) or from HCs (c). Two-sided Mann–Whitney U-test was used.